Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab + toripalimab + chemotherapy as neoadjuvant therapy for unresectable locally advanced head and neck squamous cell carcinoma
ChiCTR2500108221Phase 2Not yet recruiting
- Sponsor
- Foshan First People's Hospital
- Start
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nimotuzumab and toripalimab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Foshan First People's Hospital. Primary endpoints: Complete Response Rate and Quality of life. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
nimotuzumabtoripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500108221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108221.